A preclinical trial demonstrated MPS1/TTK inhibitors have anti-proliferative effects in basal BC cell lines, with the half-maximal inhibitory concentration (IC50) values ranging from 0.05 to 1.0 μM (42). The gene discussed is TTK; the disease is breast cancer.